Compare · INVA vs JNJ
INVA vs JNJ
Side-by-side comparison of Innoviva Inc. (INVA) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INVA and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 405.0x INVA ($1.51B).
- Over the past year, INVA is up 20.4% and JNJ is up 32.3% - JNJ leads by 11.8 points.
- JNJ has been more active in the news (16 items in the past 4 weeks vs 1 for INVA).
- JNJ has more recent analyst coverage (25 ratings vs 11 for INVA).
- Company
- Innoviva Inc.
- Johnson & Johnson
- Price
- $20.78-0.29%
- $255.53+0.88%
- Market cap
- $1.51B
- $610.38B
- 1M return
- -1.26%
- -5.45%
- 1Y return
- +20.43%
- +32.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 1
- 16
- Recent ratings
- 11
- 25
Innoviva Inc.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest INVA
- Oppenheimer resumed coverage on Innoviva with a new price target
- Innoviva to Participate in Upcoming Investor Conferences
- Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 56,389 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares, decreasing direct ownership by 0.40% to 284,799 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Basso Stephen covered exercise/tax liability with 558 shares, decreasing direct ownership by 0.63% to 88,013 units (SEC Form 4) to cover withholding tax
- Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
- SEC Form 10-Q filed by Innoviva Inc.
- Innoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
- Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause